Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 53-56

  Henderson, David C ^a,b   Freudenreich, Oliver ^a,b   Borba, Christina P C ^a,b   Wang, Xingyue ^a   Copeland, Paul M ^a,b   Macklin, Eric ^a,b   Fan, Xiaoduo ^a,b   Cather, Corinne ^a,b   Goff, Donald C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clozapine; Glucose metabolism; Lipids; Modafinil; Obesity

Indexed keywords

CLOZAPINE; MODAFINIL; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CLOZAPINE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPID METABOLISM; MALE; METABOLIC DISEASES; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 79960295026     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.04.009     Document Type: Article

References (30)

1. Aronne L.J., Nelinson D.S., Lillo J.L. Obesity as a disease state: a new paradigm for diagnosis and treatment. Clinical Cornerstone 2009, 9:9-25. (discussion 6-9).
2. Besset A., Chetrit M., Carlander B., Billiard M. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiologie Clinique = Clinical Neurophysiology 1996, 26:60-66.
3. Billiard M., Besset A., Montplaisir J., Laffont F., Goldenberg F., et al. Modafinil: a double-blind multicentric study. Sleep 1994, 17:S107-S112.
4. Boivin D.B., Montplaisir J., Petit D., Lambert C., Lubin S. Effects of modafinil on symptomatology of human narcolepsy. Clinical Neuropharmacology 1993, 16:46-53.
5. Connell P. Amphetamine Psychosis 1958, Oxford University Press, London.
6. De Sereville J.E., Boer C., Rambert F.A., Duteil J. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology 1994, 33:755-761.
7. DeBattista C., Doghramji K., Menza M.A., Rosenthal M.H., Fieve R.R. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. The Journal of Clinical Psychiatry 2003, 64:1057-1064.
8. Dequardo J.R. Modafinil-associated clozapine toxicity. The American Journal of Psychiatry 2002, 159:1243-1244.
9. Ferraro L., Antonelli T., O'Connor W.T., Tanganelli S., Rambert F.A., Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biological Psychiatry 1997, 42:1181-1183.
10. Freudenreich O., Henderson D.C., Macklin E.A., Evins A.E., Fan X., et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. The Journal of Clinical Psychiatry 2009, 70:1674-1680.
11. Henderson D.C. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Current Diabetes Reports 2002, 2:135-140.
12. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. The American Journal of Psychiatry 2000, 157:975-981.
13. Henderson D.C., Daley T.B., Kunkel L., Rodrigues-Scott M., Koul P., Hayden D. Clozapine and hypertension: a chart review of 82 patients. The Journal of Clinical Psychiatry 2004, 65:686-689.
14. Henderson D.C., Louie P.M., Koul P., Namey L., Daley T.B., Nguyen D.D. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Annals of Clinical Psychiatry 2005, 17:95-97.
15. Henderson D.C., Nguyen D.D., Copeland P.M., Hayden D.L., Borba C.P., et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. The Journal of Clinical Psychiatry 2005, 66:1116-1121.
16. Henderson D.C., Cagliero E., Copeland P.M., Louie P.M., Borba C.P., et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. The Journal of Clinical Psychiatry 2007, 68:533-541.
17. Holder G., Brand S., Hatzinger M., Holsboer-Trachsler E. Reduction of daytime sleepiness in a depressive patient during adjunct treatment with modafinil. Journal of Psychiatric Research 2002, 36:49-52.
18. Littner M., Johnson S.F., McCall W.V., Anderson W.M., Davila D., et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001, 24:451-466.
19. Makris A.P., Rush C.R., Frederich R.C., Kelly T.H. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004, 42:185-195.
20. Mariani J.J., Hart C.L. Psychosis associated with modafinil and shift work (letter). The American Journal of Psychiatry 2005, 1983.
21. Narendran R., Young C.M., Valenti A.M., Nickolova M.K., Pristach C.A. Is psychosis exacerbated by modafinil?. Archives of General Psychiatry 2002, 59:292-293.
22. Pawluk L.K., Hurwitz T.D., Schluter J.L., Ullevig C., Mahowald M.W. Psychiatric morbidity in narcoleptics on chronic high dose methylphenidate therapy. The Journal of Nervous and Mental Disease 1995, 183:45-48.
23. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. The Journal of Clinical Psychiatry 2007, 68:705-710.
24. Spence S.A., Green R.D., Wilkinson I.D., Hunter M.D. Modafinil modulates anterior cingulate function in chronic schizophrenia. The British Journal of Psychiatry 2005, 187:55-61.
25. Sudhakar T.P., Prasada Rao G., Lakshmi Prasuna P., John Vijay Sagar K. Study of effects of modafinil add-on therapy on excessive day time drowsiness and weight gain in patients on atypical antipsychotics. Indian Journal of Psychological Medicine 2008, 30:24-31.
26. Thompson F.E., Byers T. Dietary assessment resource manual. The Journal of Nutrition 1994, 124:2245S-2317S.
27. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
28. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363-1373.
29. Valentino R.M., Foldvary-Schaefer N. Modafinil in the treatment of excessive daytime sleepiness. Cleveland Clinic Journal of Medicine 2007, 74(561-6):8-71.
30. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. The Journal of the American Medical Association 2009, 301:1148-1154.